Latest 8-K filings

Archer-Daniels-Midland Company announces the resignation of director Lei Z. Schlitz, effective December 31, 2026, following a change in her principal employment.

United Parcel Service, Inc. has announced the issuance of $1 billion in 4.850% Senior Notes due 2031, with a portion intended for its retirement trusts.

Xilio Therapeutics announced second quarter 2026 financial results, highlighting FDA clearance for XTX501 IND and advancing masked T cell engager programs, with cash runway extending into Q1 2028.

Altimmune announced its second quarter 2026 financial results, highlighting the initiation of the global PERFORMA Phase 3 MASH trial and positive topline data from the RECLAIM Phase 2 AUD trial, alongside a robust cash balance.

Arbutus Biopharma reported Q2 2026 results, highlighting a $178M payment from Moderna settlement, progress on imdusiran's Phase 2b trial, and plans for a capital return to shareholders.

Local Bounti announced second quarter 2026 financial results, showcasing 14% revenue growth and a 17% improvement in Adjusted EBITDA loss, alongside a $12.5 million investment from a strategic investor.

CTT Pharmaceutical Holdings, Inc. announced the U.S. Patent Office has granted a continuation-in-part patent for its micelle delivery technology, now covering nicotine, vitamins, and caffeine across various oral dosage forms.

Capstone Holding Corp. announced that previously issued financial statements for periods in 2025 should no longer be relied upon due to errors in calculating weighted average shares outstanding.

Milestone Pharmaceuticals announced Q2 2026 results, highlighting a significant increase in insurance coverage for CARDAMYST to over 50% of commercially insured lives and the activation of its Phase 3 trial for atrial fibrillation.

Applied Aerospace & Defense announced record second quarter 2026 revenue of $167.3 million, up 47.4% year-over-year, alongside a successful $683 million IPO.

Zion Oil & Gas, Inc. has filed an amendment to its Dividend Reinvestment and Direct Stock Purchase Plan, introducing a new Unit Option program with specific terms for common stock and warrants.

AMCON Distributing Company has announced its official listing on the NYSE Texas Exchange, effective August 13, 2026, while maintaining its primary listing on the NYSE American.

Sutro Biopharma announced second quarter 2026 financial results, highlighting encouraging early clinical data for its STRO-004 ADC candidate and progress across its pipeline, while cash reserves remain strong.

TScan Therapeutics announced second quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 3 ALLOHA-2 study and positive initial data from its Phase 1 ALLOHA study.

Cypherpunk Technologies announced its second quarter 2026 financial results, highlighting an increase in Zcash holdings and progress for its subsidiary Leap Therapeutics' cancer drug candidate, sirexatamab.

Cycurion, Inc. confirms its Nasdaq hearing is scheduled for August 20, 2026, with its common stock continuing to trade on the Nasdaq Capital Market.

Fervo Energy announced strong operational progress in Q2 2026, including advancements in its Cape Station project and a successful $2.2 billion IPO, while reporting an operating loss of $28.7 million.

Humacyte announced positive Q2 2026 results, highlighting breakthrough Phase 3 data for its dialysis access product and progress in its coronary artery bypass graft program.

Lexeo Therapeutics announced key business highlights and financial results for Q2 2026, including the initiation of a pivotal trial for LX2006 and FDA RMAT designation for LX2020, with cash runway extending into 2028.

Acumen Pharmaceuticals announced its second quarter 2026 financial results and provided a business update, including expected topline results for its Phase 2 ALTITUDE-AD study in late 2026 and progress on its Enhanced Brain Delivery program.

Octave Intelligence plc announced its second quarter 2026 financial results, reporting a significant net loss due to impairment charges, though recurring revenue and annualized recurring revenue (ARR) showed growth.

Trimble Inc. announced robust second quarter 2026 results, highlighted by record annualized recurring revenue and raised full-year financial guidance, alongside a new $1.0 billion share repurchase authorization.

Bausch + Lomb Corporation announces amendments to its prior 8-K filing, detailing significant shifts in Board leadership and committee appointments effective August 5th and August 10th, 2026.

Sound Point Meridian Capital announced fee adjustments for the latter half of 2026 and declared distributions for its common and preferred stock, alongside first quarter 2026 financial results.

Performance Food Group Company announced robust fourth-quarter and full-year fiscal 2026 results, highlighted by significant case volume growth, increased net sales, and improved profitability, alongside providing positive financial guidance for fiscal year 2027.

Protalix BioTherapeutics announces significant revenue growth and profitability for Q2 2026, driven by Elfabrio sales and a milestone payment, while advancing its PRX-115 clinical trial.

Kontoor Brands reported a 19% revenue increase in Q2 2026, driven by Helly Hansen and Wrangler, and raised its full-year EPS outlook.

T1 Energy announced its second quarter 2026 financial results, reporting $250.1 million in net sales and $10.7 million in Adjusted EBITDA, while also detailing strategic acquisitions and progress on its G2_Austin solar fab.

Liquidia Corporation announced robust second quarter 2026 financial results, highlighted by a 31% sequential increase in YUTREPIA net product sales to $170.4 million and a fourth consecutive quarter of increasing profitability.

Nova Minerals Corp provides a comprehensive update on its 2026 field season at the Estelle Gold and Critical Minerals Project, highlighting operational progress, drilling results, and permitting advancements.